Currently out of the existing stock ratings of Etzer Darout, 233 are a BUY (81.75%), 41 are a HOLD (14.39%), 11 are a SELL (3.86%).

Etzer Darout

Work Performance Price Targets & Ratings Chart

Analyst Etzer Darout, currently employed at BARCLAYS, carries an average stock price target met ratio of 53.48% that have a potential upside of 42.11% achieved within 153 days. Previously, Etzer Darout worked at BMO.

Etzer Darout’s has documented 566 price targets and ratings displayed on 54 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SMMT, Summit Therapeutics PLC at 01-Oct-2026.

Wall Street Analyst Etzer Darout

Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 8/9/2024. The price target of $34 was fulfilled within 59 days with a profit of $25.55 (302.37%) receiving and performance score of 51.25.

Average potential price target upside

of $30.39 (23.3%) on AZN (ASTRAZENECA PLC ADR).
of $29.94 (20.94%) on SGEN (SEAGEN).
of $28.99 (31.7%) on BNTX (BIONTECH SE).

DMAC DiaMedica Therapeutics MGNX MacroGenics MIRM Mirum Pharmaceuticals VERV Verve Therapeutics CTMX CytomX Therapeutics EXEL Exelixis FATE Fate Therapeutics GMAB Genmab AS IMGN ImmunoGen MRUS Merus BV SGEN Seagen NUVL Nuvalent XNCR Xencor FPRX Five Prime Therapeutics ALNY Alnylam Pharmaceuticals YMAB Y mAbs Therapeutics ARVN Arvinas FTSV Forty Seven AZN AstraZeneca PLC ADR CCCC C4 Therapeutics IVA Inventiva Sa BNTX BioNTech SE IGMS IGM Biosciences NVS Novartis AG ADR SRRK Scholar Rock Holding Corp TERN Terns Pharmaceuticals ACRV Acrivon Therapeutics QTTB Q32 Bio MYOK MyoKardia KYMR Kymera Therapeutics PTGX Protagonist Therapeutics RAPT RAPT Therapeutics ANAB AnaptysBio CLDX Celldex Therapeutics CRVS Corvus Pharmaceuticals INCY yte IOVA Iovance Biotherapeutics JANX Janux Therapeutics SMMT Summit Therapeutics PLC ABVX Abivax SA ACRS Aclaris Therapeutics ORKA Oruka Therapeutics VBLT Vascular Biogenics Ltd ZYME Zymeworks AKRO Akero Therapeutics FBRX Forte Biosciences FHTX Foghorn Therapeutics JAZZ Jazz Pharmaceuticals PLC LEGN Legend Biotech Corp MNPR Monopar Therapeutics NRIX Nurix Therapeutics RLAY Relay Therapeutics SNDX Syndax Pharmaceuticals TRML Tourmaline Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)

Buy Since 07-Oct-2024

$12

$4.43 (58.52%)

$12

2 months 11 days ago
(11-Aug-2026)

2/8 (25%)

$5.13 (74.67%)

317

Please subscribe to see extended stock data

Thomas Flaten (LAKE STREET)

Buy Since 15-May-2020

$14

$6.43 (84.94%)

$14

6 months 22 days ago
(30-Mar-2026)

0/4 (0%)

$7.36 (110.84%)

Please subscribe to see extended stock data

Joshua Schimmer (CANTOR FITZGERALD)

Buy Since 30-Mar-2026

$25

$16.77 (203.77%)

$25

6 months 22 days ago
(30-Mar-2026)

0/2 (0%)

$18.36 (276.51%)

Please subscribe to see extended stock data

Chase Knickerbocker (CRAIG HALLUM)

Buy Since 24-Apr-2024

$11

$4.45 (67.94%)

1 years 3 months 4 days ago
(18-Jul-2025)

1/2 (50%)

$6.82 (163.16%)

579

Please subscribe to see extended stock data

Francois Brisebois (OPPENHEIMER)

Buy Since 21-Mar-2024

$-0.55 (-8.40%)

2 years 2 months 6 days ago
(16-Aug-2024)

3/5 (60%)

$2.4 (66.67%)

403

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Etzer Darout most bullish on?

Potential upside of $85.52 has been obtained for ORKA (ORUKA THERAPEUTICS)

Which stock is Etzer Darout most reserved on?

Potential downside of -$13.23 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Etzer Darout?

On 2016